Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety

PURPOSE: Survival of platinum-resistant ovarian cancer (PROC) patients is significantly shortened to around 12 months. Anlotinib is a new multi-target tyrosine kinase inhibitor. The goal of this study is to evaluate the efficacy and safety of anlotinib in PROC patients. PATIENTS AND METHODS: PROC pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Jing, Cheng, Xianzhong, Chen, Jin, Guo, Wenwen, Dai, Zhiqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547134/
https://www.ncbi.nlm.nih.gov/pubmed/33116571
http://dx.doi.org/10.2147/OTT.S268613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547134/
https://www.ncbi.nlm.nih.gov/pubmed/33116571
http://dx.doi.org/10.2147/OTT.S268613

Ejemplares similares